1 / 21

Reaching for Prevention: Era of Hope in Oncology and Metabolic Research

Reaching for Prevention: Era of Hope in Oncology and Metabolic Research. Our Model. Research University. PVLSI. Hospital. Baystate Medical Center Tufts teaching hospital Serves a patient population of ~1M people More than 1,000 physicians Baystate Reference Lab Tissue Bank

ovidio
Download Presentation

Reaching for Prevention: Era of Hope in Oncology and Metabolic Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reaching for Prevention: Era of Hope in Oncology and Metabolic Research

  2. Our Model Research University PVLSI Hospital

  3. Baystate Medical Center Tufts teaching hospital Serves a patient population of ~1M people More than 1,000 physicians Baystate Reference Lab Tissue Bank >300 new cases of breast cancer. >300 cases of bariatric surgery UMass, Amherst 8 schools and colleges 21,373 undergraduate; 6,196 graduate students 1,174 full-time faculty Degrees granted in over 200 areas >$170 million in sponsored research in 2010 Our Partners

  4. Our Goals • Advance translational biomedical research • Improve diagnosis and treatment of diseases • Support collaborative projects • Enhance medical and scientific education • Recruitment and retention of clinicians, residents, scientists, post-doctoral fellows, and graduate students • Participate in regional economic growth • Create a biotech nucleus in Springfield • Creation of jobs • Recruitment of companies and facilitate start-ups

  5. Goals in translational biomedicine

  6. Incidence of cancers by site Breast cancer: >2X of other cancers From Jemal, A. et al. CA Cancer J Clin 2010;60:277-300.

  7. Age-standardized incidence per 100,000 for breast From GLOBOCAN 2008 (IARC) – 23:1, 2011 .

  8. Mortality from breast cancer Developed countries Developing countries From International Agency for Research on Cancer (IARC) – 23:1, 2011 .

  9. Shared basis for risk of common disease Prevalence 1990 All < 15% 2009 All > 15% No Data <10% 10%–14% 15%–19% 20%–24% 25%–29% ≥30% Source: Behavioral Risk Factor Surveillance System, Center for Disease Control (http://www.cdc.gov/obesity/data/trends.html)

  10. Source: 2005–2008 National Health and Nutrition Examination Survey.

  11. Therapeutics: blocking angiogenesis Provided by Dr. Rong Shao PVLSI

  12. ADH Diagnostics: Subtypes of atypical hyperplasia Micro-dissect LCIS Subtypes of Atypical Hyperplasias Subtypes of lesions with malignant potential Provided by Center for Breast Cancer Research

  13. Therapies: Avoiding loss of EPCs • Targeted enhancement of viability and maintain function. Provided by Dr. Saby Sen, MD

  14. Insulin Sensitivity 120 Wild Type 110 Gene KO 100 90 Glucose (% initial) 80 70 60 ** 50 ** ** 40 0 20 40 60 80 100 120 140 Therapies: Preserving pancreatic function • Expanding the pancreatic beta cells. • Improving glucose homeostasis. Wild Type Gene KO Provided by Dr. Alan Schneyer, PhD

  15. Biopolymers for delivery and detection Provided by Dr. Todd Emrick, PhD

  16. Improved distribution of doxorubicin NP-Dox Dox Necrotic cells Provided by Dr. Neil Forbes

  17. PVLSI Collaborators (1) • Seahorse Bioscience • Makers of analytical instruments and consumable labware • Extracellular flux technology measures cellular bioengergetics in an non-invasive, micro well plate • PVLSI is working with Seahorse to validate new applications for the XF Analyzer

  18. PVLSI Collaborators (2) • Biomedical Research Models • Conducts specialty contract research • Unique expertise in animal research, especially diabetes • Drug testing platform • Development of new disease models

  19. CEAR Translational Research Grants • Funded through the Center of Excellence in Apoptosis Research (CEAR) • CEAR dollars are matched by corporate sponsors • Applicants must be CEAR Investigators and proposing translational biomedical research projects

  20. Facilities

  21. 3601 Main Street • 25, 000 Square ft. of newly renovated lab space • 5, 000 Square ft. of animal research facility • 15,000 Square ft. of future expansion space

More Related